Show Stocks and Investing Publications • Fri, November 4, 2022
Salveen Richter Downgraded (ACAD) to Strong Sell and Decreased Target to $12 on, Nov 4th, 2022
wngraded-acad-to-strong-sell-and-decreased-target-to-12-on-nov-4th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAISalveen Richter of Goldman Sachs, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Sell and Decreased Target from $15 to $12 on, Nov 4th, 2022.
Salveen has made no other calls on ACAD in the last 4 months.
There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 4 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022
- Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $19 on, Wednesday, August 10th, 2022
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $18 on, Tuesday, August 9th, 2022
- Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $15 on, Monday, August 8th, 2022
These are the ratings of the 4 analyists that currently disagree with Salveen
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $25 on, Tuesday, August 9th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $21 on, Tuesday, August 9th, 2022
- Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $21 on, Monday, August 8th, 2022
Like: 👍